Investment Rating - The report maintains a "Buy" rating for H&H International Holdings (01112.HK) [1] Core Insights - H&H International Holdings reported a revenue of 14.35 billion RMB for 2025, reflecting a year-on-year growth of 9.97%. The adjusted EBITDA and net profit were 2.05 billion RMB and 670 million RMB, respectively, with year-on-year increases of 5% and 23% [7] - The company has shown resilience in its infant probiotics and nutritional products segment, achieving a revenue growth of 2% in 2025, a significant recovery from a decline of 32% in 2024. This growth is attributed to new product launches and an increase in e-commerce sales [7] - The management's strategic focus on long-term growth and compliance has led to a proactive adjustment of its business model, particularly in the Australian and New Zealand markets, which is expected to enhance future growth [7] Financial Projections - The projected total revenue for H&H International Holdings is expected to reach 20.07 billion RMB by 2028, with a compound annual growth rate (CAGR) of approximately 11.71% from 2025 to 2028 [1] - The forecasted net profit for 2026 and 2027 is adjusted to 634.78 million RMB and 873.64 million RMB, respectively, indicating a year-on-year growth of 224% and 38% [7] - The earnings per share (EPS) is projected to increase from 0.30 RMB in 2025 to 1.73 RMB by 2028, reflecting a strong upward trend in profitability [1][7] Market Data - The closing price of H&H International Holdings is 12.45 HKD, with a market capitalization of 7.08 billion HKD. The stock has a price-to-earnings (P/E) ratio of 36.06 based on the latest diluted EPS [5][6] - The company has a net asset value per share of 9.28 RMB and a debt-to-asset ratio of 69.12%, indicating a relatively high leverage position [6]

Investment Rating - The investment rating for H&H International Holdings is "Buy" (maintained) [1] Core Views - H&H International Holdings reported its 2025 annual performance, achieving revenue of 14.35 billion RMB, a year-on-year increase of 10% [7] - The company demonstrated resilience in its infant probiotics and nutritional products segment, with revenue stabilizing at a 2% year-on-year growth, contrasting with a decline of 32% in 2024 [7] - The management's strategic focus on long-term growth and compliance has been highlighted, particularly in the Australian and New Zealand (ANC) market, where revenue growth is expected despite a temporary contraction due to regulatory adjustments [7] Financial Summary - Total revenue projections for H&H International Holdings are as follows: 13.05 billion RMB for 2024, 14.35 billion RMB for 2025, 16.04 billion RMB for 2026, 17.97 billion RMB for 2027, and 20.07 billion RMB for 2028, with respective year-on-year growth rates of -6.28%, 9.97%, 11.76%, 12.02%, and 11.71% [1][8] - The net profit attributable to the parent company is forecasted to be -53.72 million RMB for 2024, 196.14 million RMB for 2025, 634.78 million RMB for 2026, 873.64 million RMB for 2027, and 1.12 billion RMB for 2028, reflecting significant growth rates of -109.23%, 465.11%, 223.64%, 37.63%, and 27.89% respectively [1][8] - The latest diluted EPS is projected to be -0.08 RMB for 2024, 0.30 RMB for 2025, 0.98 RMB for 2026, 1.35 RMB for 2027, and 1.73 RMB for 2028 [1][8] - The current P/E ratios are 131.66 for 2024, 36.06 for 2025, 11.14 for 2026, 8.10 for 2027, and 6.33 for 2028 [1][8]

Investment Rating - The report maintains a "Buy" rating for H&H International Holdings (01112.HK) [1] Core Views - The management is actively pursuing growth strategies, indicating a clear growth ambition alongside a new product cycle, which is expected to resonate positively with the company's performance [7] - The company is projected to achieve a significant turnaround in profitability, with a forecasted net profit of 276.77 million in 2025, representing a 615.21% year-on-year increase [7] - The report highlights strong revenue growth in the BNC and infant formula segments, with expected growth rates of 20-30% for infant formula and low single-digit growth for probiotics and nutritional products [7] Financial Projections - Total revenue is forecasted to reach 14,447 million in 2025, reflecting a 10.69% year-on-year increase [1] - The adjusted EBITDA and net profit are expected to grow by 2-6% and 15-25% respectively in 2025, with an overall adjusted net profit margin projected to be in the mid-single digits [7] - The company anticipates a cash balance exceeding 1.7 billion by 2025, which will support its debt reduction efforts and optimize interest expenses in 2026 [7] Valuation Metrics - The report provides a P/E ratio forecast of 28.84x for 2025, decreasing to 9.05x by 2027, indicating an attractive valuation as earnings improve [1][7] - The projected EPS for 2025 is 0.43, with further increases to 0.99 in 2026 and 1.37 in 2027 [1]